Abstract
Only limited data have been published about the therapeutic use of anakinra in patients with psoriatic arthritis. We undertook this study to evaluate the efficacy and safety of anakinra in patients with active psoriatic arthritis. In a prospective open-label single-center study, 20 patients were treated with 100 mg anakinra everyday either alone or in combination with ongoing methotrexate over 6 months. Safety and efficacy was evaluated using Psoriasis Arthritis Response Criteria (PsARC), Disease Activity Score (DAS) 28, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), Psoriasis Area and Severity Index Score, Dactylitis Score and Health Assessment Questionnaire (HAQ), and the C-reactive protein, and erythrocyte sedimentation rate. Of the 20 patients enrolled, six completed 24 weeks, 18 completed 12 weeks, and 19 completed 4 weeks of treatment. Early-treatment termination was mainly due to inefficacy (13 patients) and only one drop-out occurred because of an unrelated adverse event. Six patients fulfilled continuously the PsARC until week 24. A moderate EULAR response was achieved by four patients and a good EULAR response by three patients in week 24. Five patients reached ACR 20, four patients ACR 50, and two patients ACR 70 in week 24. HAQ improved slightly throughout the study (n = 19, mean (SD); baseline, 1.127 (0.671); week 24, 1.055 (0.812)) just as DAS 28 (n = 16; baseline, 4.7(1.5); week 24, 4.0(2.0)). Only nine patients showed skin manifestations affecting >3% of their body surface area which improved in two, worsened in four, stabilized in two patients, and newly evolved in one patient. Adverse events were mainly mild (95%). Fifteen (75%) patients showed injection site reactions. No serious infections occurred. Anakinra was well tolerated with no occurrence of serious drug-associated adverse events and lead to improvement of signs and symptoms in nine out of 19 patients, therefore providing a potential therapeutic option in patients with active psoriatic arthritis.
References
Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361(5):496–509
Gladman DD et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17
Ritchlin CT et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394
Gottlieb A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58(5):851–864
Furst DE et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66(Suppl 3):iii2–iii22
Mease PJ, Antoni CE (2005) Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64(Suppl 2):ii78–ii82
Cohen S et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614–624
Pascual V et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479–1486
Fitzgerald AA et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52(6):1794–1803
Botsios C et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4):284–286
Shinkai K, McCalmont TH, Leslie KS (2008) Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 33(1):1–9
de Koning HD et al (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3):137–148
Furlan A et al (2008) Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 75(3):366–367
Kalliolias GD, Liossis SN (2008) The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17(3):349–359
Gibbs A et al (2005) Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study. Arthritis Res Ther 7(Suppl 1):P68
Konttinen L et al (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25(6):882–884
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78
Mease PJ et al (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii49–ii54
Felson DT et al (1995) American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735
Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157(4):238–244
Hollis S, Campbell F (1999) What is meant by intention to treat analysis? Survey of published randomised controlled trials. Bmj 319(7211):670–674
Burger D et al (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20(5):879–896
Dinarello CA (2005) The many worlds of reducing interleukin-1. Arthritis Rheum 52(7):1960–1967
Fleischmann RM et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006–1012
Fleischmann RM (2003) Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl 2):ii29–ii35
Acknowledgments
We thank G. Mahrle for help with the study protocol and for recruiting patients into the study. We thank U. Harnischmacher for help with the analysis. We also would like to thank Axel Münz Amgen GmbH, Munich Germany, for his continuous support.
Disclosures
Dr. Norma Jung: none
Dr. Matthias Hellmann: none
Dr. Clara Lehmann: none
Dr. Reimund Hoheisel: none
Dr. Andreas Perniok: none
Prof. Dr. Michael Hallek: none
Dr. Rubbert-Roth has received honorarium for consultation and talks from Amgen, Wyeth, Essex, Roche, BMS, MSD, Abbott, and Chugai.
Dr. Haase has received honorarium from Merck/Serono, Leo Pharma, Wyeth, and Abbott.
Author information
Authors and Affiliations
Corresponding author
Additional information
Norma Jung and Matthias Hellmann contributed equally.
Rights and permissions
About this article
Cite this article
Jung, N., Hellmann, M., Hoheisel, R. et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 29, 1169–1173 (2010). https://doi.org/10.1007/s10067-010-1504-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1504-5